





GUJARAT TERCE LABORATORIES LIMITED

Statement of Unaudited Standalone Financial Results for the Quarter Ended 30/06/2025 [Rs.In Lakhs except per share detail]					
	Particulars	Quarter ended			Year ended
		30-06-2025	31-03-2025	30-06-2024	31-03-2025
		Unaudited	Audited	Unaudited	Audited
	1	2	3	4	5
I.	Revenue from operations	1085.36	1232.44	1188.88	5019.52
II.	Other income	9.48	8.67	7.33	30.78
III.	Total Revenue (I+II)	1094.84	1241.11	1196.21	5050.30
IV.	Expenses:				
	a) Cost of Material consumed	198.38	305.61	333.84	914.31
	b) Purchase of stock in trade	258.99	267.40	298.31	1014.85
	c) Changes in inventories of finished goods, WIP and stock in trade.	-15.31	-22.24	-127.86	-38.14
	d) Employees benefits expenses.	374.86	416.58	383.57	1618.93
	e) Finance Costs	4.93	6.86	12.83	41.54
	f) Depreciation and amortisation exp.	9.61	10.25	9.24	38.46
	g) Other Expenses	270.48	159.82	293.22	1121.31
	Total Expenses	1101.94	1144.28	1203.15	4711.26
V	Profit/(Loss) before exceptional and Extra ordinary items and Taxes.(III - IV)	-7.10	96.83	-6.94	339.04
VI	Exceptional items.	0.00	0.00	0.00	0.00
VII	Profit/(Loss) before extraordinary items and Tax (V-VI)	-7.10	96.83	-6.94	339.04
VIII	Extraordinary items	0.00	0.00	0.00	0.00
IX	Profit/(Loss) before Tax (VII-VIII)	-7.10	96.83	-6.94	339.04
X	Tax Expenses				
	1) Current Tax	0.00	16.36	0.00	16.36
	2) Deferred Tax	-2.75	77.90	0.82	78.84
	3) Income-Tax of Earlier Year	0.00	341.71	0.00	341.71
XI	Profit/(Loss) for the period from continuing operations (IX-X)	-4.35	-339.14	-7.76	-97.87
XII	Other Comprehensive Income				
	Re-measurement losses on post employment defined benefit plans	0.00	0.00	0.00	0.00
	Income Tax effect	0.00	0.00	0.00	0.00
	Total	0.00	0.00	0.00	0.00
	Net loss/(gain) on Fair Value through OCI (FVTOCI) on equity securities	0.00	0.00	0.00	0.00
XIII	Other Comprehensive Income for the period, net of tax	0.00	0.00	0.00	0.00
XIV	Total Comprehensive Income for the period (XI+XII)	-4.35	-339.14	-7.76	-97.87
XV	Paid up Equity Capital (at par value of Rs. 10 each)	742.03	742.03	742.03	742.03
XVI	Earning per equity share				
	a) Basic	-0.06	-4.57	-0.10	-1.31
	b) Diluted	-0.06	-4.35	-0.10	-1.26
	(See accompanying notes to the Financial Results)				
Place:Ahmedabad		<div>For Gujarat Terce Laboratories Limited</div> <div></div> <div>Aalap Prajapati</div> <div>Whole Time Director</div> <div>DIN: 08088327</div>			
Date:11/08/2025					
Notes:					
1	The above Unaudited Financial Results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on August 11, 2025				
2	The Limited Review Report for the quarter ended 30.06.2025 has been carried out by the statutory auditor, as required under Regulation 33 of SEBI (LODR) Regulation, 2015.				
3	The Company has adopted Indian Accounting Standard ("Ind AS") notified by the Ministry of Corporate Affairs with effect from April 01, 2017 and accordingly these Audited financial results of the company for the quarter and year ended 30.06.2025 has been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.				
4	The Company is operating in single (Pharmaceutical) segment, so above Unaudited Financial Results are for single segment only.				
5	The figures of the previous quarter / periods has been regrouped/reclassified, wherever necessary.				

Limited Review Report for unaudited standalone quarterly and year to date results

We have reviewed the accompanying statement of unaudited financial results of Gujarat Terce Laboratories Limited for the quarter ended on June, 2025. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Companies (Indian Accounting Standards) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 11th August 2025

Place: Anand

For, M. A. Shah & Co.
Chartered Accountants
FRN: 0112630W



Param Doshi, FCA
(Partner)

Mem. No: 185648

UDIN: 25185648BMOOMS6263

